Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alcanna Inc. stock logo
CLIQ
Alcanna
C$9.05
C$5.89
C$10.20
C$327.85MN/A253,253 shs555,803 shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
$23.47
-0.1%
$23.79
$21.69
$24.28
$2.73B0.12861,488 shs424,984 shs
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
$23.78
-1.0%
$23.97
$20.16
$25.15
$2.38M0.91,475 shs110 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alcanna Inc. stock logo
CLIQ
Alcanna
0.00%0.00%0.00%0.00%0.00%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
-0.13%-0.57%-1.47%-1.51%-1.01%
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
-1.04%+1.89%-4.69%+16.28%+2,377,999,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alcanna Inc. stock logo
CLIQ
Alcanna
N/AN/AN/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
N/AN/AN/AN/AN/AN/AN/AN/A
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alcanna Inc. stock logo
CLIQ
Alcanna
N/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/A
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
0.00
N/AN/AN/A
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alcanna Inc. stock logo
CLIQ
Alcanna
C$726.27M0.00N/A7.66C$4.49 per share0.00
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
N/AN/AN/AN/AN/AN/A
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alcanna Inc. stock logo
CLIQ
Alcanna
N/AC$1.028.87N/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
N/AN/A0.00N/AN/AN/AN/AN/A
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alcanna Inc. stock logo
CLIQ
Alcanna
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
$0.622.64%N/AN/AN/A
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
$0.010.04%N/AN/AN/A

Latest GBT, CLIQ, ZZZ, and PZA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/26/2024
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
Quarterly$0.01183/27/20243/28/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alcanna Inc. stock logo
CLIQ
Alcanna
121.51
3.35
1.03
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
N/AN/AN/A
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alcanna Inc. stock logo
CLIQ
Alcanna
2,26436.23 millionN/ANot Optionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
Invesco National AMT-Free Municipal Bond ETF stock logo
PZA
Invesco National AMT-Free Municipal Bond ETF
N/A116.25 millionN/ANot Optionable
ZZZ
Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF
N/A100,000N/AN/A

GBT, CLIQ, ZZZ, and PZA Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alcanna logo

Alcanna

TSE:CLIQ
Alcanna Inc. engages in the retailing of alcohol in North America. The company retails wines, beers, and spirits; and cannabis products It operates 176 locations in Alberta and British Columbia; and 53 cannabis retail stores in Alberta, Ontario, and Saskatchewan. The company was formerly known as Liquor Stores N.A. Ltd. and changed its name to Alcanna Inc. in May 2018. Alcanna Inc. was founded in 2004 and is headquartered in Edmonton, Canada. As of March 30, 2022, Alcanna Inc. operates as a subsidiary of Sundial Growers Inc.
Global Blood Therapeutics logo

Global Blood Therapeutics

NASDAQ:GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Invesco National AMT-Free Municipal Bond ETF logo

Invesco National AMT-Free Municipal Bond ETF

NYSEARCA:PZA
The Invesco National AMT-Free Municipal Bond ETF (PZA) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund tracks an index of investment grade, tax-exempt debt publicly issued by a US state with at least 15 years remaining to maturity. PZA was launched on Oct 11, 2007 and is managed by Invesco.

Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF

NASDAQ:ZZZ
The Cyber Hornet S&P 500 and Bitcoin 75/25 Strategy ETF (ZZZ) is an exchange-traded fund that mostly invests in target outcome asset allocation. The fund tracks an index that provides 75/25 exposure to US large-cap stocks and front-month CME Bitcoin futures, respectively. The fund does not directly invest in Bitcoin, nor does it maintain direct exposure to its spot price. ZZZ was launched on Dec 28, 2023 and is issued by Onefund.